Study #2023-0356
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of ABSK021 to assess the efficacy and safety in patients with Tenosynovial Giant Cell Tumor.
MD Anderson Study Status
Not Accepting
Treatment Agent
Pimicotinib(ABSK021), Placebo
Description
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: * Whether the Pimicotinib(ABSK021) works well in patients with TGCT. * Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. * Complete the study procedures speficied in the protocol, which is guided by researchers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Study phase:
Phase III
Physician name:
Vinod Ravi
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-844-635-1016
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.